Switching from ACE Inhibitor to Losartan for Itching
If a patient develops itching (pruritus) from an ACE inhibitor, switching to losartan is NOT appropriate—you should discontinue the ACE inhibitor and consider alternative antihypertensive classes entirely, as itching suggests a potential hypersensitivity reaction rather than the classic bradykinin-mediated side effects (cough or angioedema) where ARBs might be considered.
Critical Distinction: Itching vs. Cough/Angioedema
The question asks about "itching," which is fundamentally different from the well-documented ACE inhibitor side effects:
ACE Inhibitor-Induced Cough
- For cough specifically, switching to an ARB like losartan is well-supported. Guidelines recommend that when persistent or intolerable ACE inhibitor-induced cough occurs, therapy should be switched to an ARB, with which the incidence of cough is similar to placebo 1.
- Clinical trials demonstrate losartan produces cough in only 17-29% of patients with prior ACE inhibitor-induced cough, compared to 62-69% with lisinopril rechallenge 2.
Itching/Pruritus: A Different Mechanism
Itching is not a bradykinin-mediated effect. When itching occurs with ACE inhibitors, this suggests:
- Possible hypersensitivity reaction
- Potential precursor to angioedema
- Immune-mediated mechanism involving circulating antibodies 3
The Angioedema Risk with ARB Switching
Critical safety concern: Even for the "approved" switch scenario (angioedema), there is a 10-32% cross-reactivity rate when switching from ACE inhibitors to ARBs 4, 5, 6.
The guideline states: "A modest risk of recurrent angioedema exists in patients who experienced angioedema in response to ACE-I therapy and then are switched to ARB therapy" 7. Importantly, angioedema can occur with ARBs even without prior ACE inhibitor exposure 2.
Recommended Approach for Itching
Discontinue the ACE inhibitor immediately and:
Do NOT switch to an ARB (losartan or otherwise) for itching
Choose an alternative antihypertensive class:
- Calcium channel blockers
- Beta-blockers
- Thiazide diuretics
- Other classes based on comorbidities
Monitor closely for progression to angioedema, as itching may represent early hypersensitivity
If there is compelling need for renin-angiotensin system blockade (e.g., diabetic nephropathy, heart failure with reduced ejection fraction):
- Consider ARB only with extreme caution
- Start with close observation
- Educate patient extensively on angioedema signs (facial/tongue/throat swelling)
- Ensure emergency management plan is in place 4
When ARB Switching IS Appropriate
ARB switching should be reserved exclusively for:
- ACE inhibitor-induced cough (Grade A recommendation) 1
- Patients with high therapeutic need for angiotensin inhibition who developed cough (not itching/rash)
The FDA label confirms losartan's safety profile specifically addresses cough, not pruritic reactions 2.
Common Pitfall to Avoid
Do not assume all ACE inhibitor side effects are equivalent. Cough is bradykinin-mediated and class-specific but mechanism-different from ARBs. Itching/rash suggests immune-mediated hypersensitivity that may cross-react with ARBs through shared angiotensin system effects or other mechanisms 3.